NeoPharm maintained at buy by Merrill

NeoPharm, Inc. was maintained by Merrill Lynch analyst David Munno at a buy on the company's uneventful fourth-quarter earnings. Guidance for 2006 was a net loss of $39 million to $41 million, or a loss of $1.40 to $1.48 per share. The next event for the company is likely the interim analysis at 160 deaths for the Precise trial, expected in June or July. Shares of the Lake Forest, Ill., pharmaceutical company were up 33 cents, or 3.26%, at $10.45 on volume of 431,072 shares versus the three-month running average of 844,983 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.